Characterizing the adhesive properties of cytokine receptor IL17Ra during brain development by Park, Ashley
Wellesley College
Wellesley College Digital Scholarship and Archive
Honors Thesis Collection
2016
Characterizing the adhesive properties of cytokine
receptor IL17Ra during brain development
Ashley Park
apark@wellesley.edu
Follow this and additional works at: https://repository.wellesley.edu/thesiscollection
This Dissertation/Thesis is brought to you for free and open access by Wellesley College Digital Scholarship and Archive. It has been accepted for
inclusion in Honors Thesis Collection by an authorized administrator of Wellesley College Digital Scholarship and Archive. For more information,
please contact ir@wellesley.edu.
Recommended Citation












Characterizing the adhesive properties of cytokine receptor IL17Ra 




Department of Neuroscience 
Wellesley College 




Gloria Choi and Yeong Shin Yim 




















This material is submitted as partial fulfillment of a B.A. degree with Honors in Neuroscience. 




Autism spectrum disorder (ASD) is a common neurodevelopmental disorder that is 
mainly characterized by three different deficits – social behavior, communication, and 
characteristic repetitive behaviors. Many human studies revealed the significant effect of 
environmentally-induced maternal immune activation (MIA) during pregnancy in the 
pathogenesis of ASD, especially in genetically vulnerable individuals. This observation has been 
modeled in MIA rodents to better understand the neural basis of MIA-induced ASD deficits. 
Although many studies have hinted at the importance of the T helper 17 (Th17) cell pathway in 
the pathogenesis of ASD, the exact immune cell populations responsible for inducing ASD-like 
phenotypes in MIA animal models have not been identified. A recent study revealed that 
interleukin-17a (IL-17a), the effector cytokine of Th17 cells, is a critical regulator of 
neurodevelopment, thus suggesting the importance of its receptor IL17Ra in causing ASD-like 
phenotypes in the MIA models as well.  
 
In this study, we aimed to characterize the role of the cytokine receptor IL17Ra in various 
neurodevelopmental processes. We had hypothesized that the protein potentially acts as a cell 
adhesion molecule to critically regulate the cellular phenotypes during cell adhesion, neurite 
outgrowth, and synapse formation. Contrary to our hypothesis, we demonstrated that IL17Ra 
inhibits, rather than stimulates, cell adhesion, as cell adhesion levels of IL17Ra-overexpressing 
non-neuronal cells were lower than those of control cells. IL17Ra expression in wild type 
primary cortical neurons also suppressed neurite outgrowth and synapse puncta formation, 
further supporting the inhibitory role of the protein. Possible mechanisms by which IL17Ra is 
involved in neurodevelopment and the implications will be discussed. Further elucidation of the 
role of IL17Ra could lead to more definitive therapeutic and preventative tools for ASD, as 
targeting of Th17 cells in conjunction with regulating IL17Ra expression in susceptible pregnant 
mothers may allow us to reduce the likelihood of bearing children with inflammation-induced 



















I am deeply indebted to the members of the Choi Lab at MIT for first exposing me to 
real-life science. I do not know if I will ever find such a wonderfully kind, goofy, yet brilliant 
group of scientists. I am especially thankful to Professor Gloria Choi for providing me with this 
incredible research opportunity. You have been an unbelievable mentor and my source of 
motivation. You never fail to impress me with how amazing of a professor, mentor, and mother 
you are to your daughters and to the lab. Also, my sincerest thank you to Yeong Shin Yim, who 
has been both a mentor and a sister to me. Thank you for being the prime example of what it 
takes to be a successful scientist, mentor, and a friend. You are the reason why I’ve made it this 
far. Most of all, however, I am grateful to the academics I met at Wellesley who taught me how 
to read scientific journals, think critically, and write – how to put the mess of thoughts in my 
head into meaningful questions and words on a page: Professor Deborah Bauer, Professor 
Barbara Beltz, Professor Margaret Keane, and my advisor, Professor Adam Matthews. 
Professor Keane, your kind and thoughtful words of encouragement always reminded me 
of the most important things in my life, at the times I needed them the most. Thank you for 
believing in me more than I believed in my own potentials.  
Professor Matthews, you have been my rock through this entire process. Thank you for 
guiding me in the right direction when I was so lost. Thank you for motivating me with kind 
words (and chocolate) when I was so down. Thank you for distracting me with your influenza 
model when I was so overwhelmed. I can’t believe how lucky I was to meet you in cell 
physiology lab; that class gave me the best thesis advisor I could ever ask for.  
This thesis would also not have been possible without the patience and kindness of my 
friends who have impacted my life and shaped my Wellesley career in every way possible. 
Particularly to TKP - The Korean Premeds - thank you. To Aileen Ro, Julia Kim, Lois Kwon, 
Rachel Han, and our honorary non-premed member Eunice Kim: thank you so much for 
laughing, crying, and growing with me over the last four years. I truly cannot imagine Wellesley 
without you. 
To Justin Peng Chen and Kevin Chin: A heartfelt thank you for giving up your game time 
to give me feedback and encouragement. I know how big of a sacrifice that must have been for 
you. I owe you galbitang. 
To Aileen Ro: Thank you for your patience, your encouragement, your commentaries and 
critiques. I will never forget the moment you offered me help on my thesis to “learn more about 
what has been such a big part of my life this year.” You are always so genuine and I am truly 
grateful to have you in my life. All scholarship is created from collaborative efforts and you have 
certainly contributed to mine.  
To my thesis buddy-in-crime Lois Kwon a.k.a. Sup3rman’s girl: We have gone through 
so much together throughout this entire process - from living alone on a deserted campus during 
Wintersession, to spontaneous trips to Area Four (AFTER dinner), and to many, many late nights 
together. Writing a thesis was definitely a challenge and a commitment, but looking back, I am 
sure I will only remember the special memories I had with you. Thank you for always having my 
back.  
To Mom, Dad, and Tommy: I can’t believe how fast another four years have gone by. 
Thank you for sending me to Wellesley. Thank you for always being my biggest fans and 
supporters. Your sacrifices and your love are the reasons why I’m here today.  
 
 iii 
TABLE OF CONTENTS 
 
Chapter 1: Introduction 
• Autism spectrum disorder (ASD) and its etiology…………………..................................1 
• Maternal immune activation (MIA)……………………………….........................….......2 
• Cross-talk between the mothers and embryo………………………………….……….....4 
• MIA rodent models…….………………………………………………….………….......5 
• T helper (Th)/ IL-17 pathway…………...……………………………………….……….6 
• MIA neurodevelopment, and ASD………………………………………………….…...10 
• Thesis aims.....………………………………………………………………………...….13 
 












Chapter 5: General Discussion 
• Potential role of IL17Ra in the pathogenesis of ASD…....……………............................47 
• Therapeutic and preventative implication..…………………………...………………….49 
 



















LIST OF FIGURES 
 
Figure 1: MIA-induced mothers express elevated IL-17a levels, leading to elevated IL-17Ra 
mRNA levels and abnormal cortical development in the offspring....…………….………….…..8 
 
Figure 2: The proposed mechanism by which the maternal Th17/IL-17 pathway induces MIA-
dependent behavioral and cortical abnormalities in the offspring. ……………………………....9 
 
Figure 3: Topology of IL17Ra………………………….…………………………………....….12 
 
Figure 4: The potential role of IL17Ra as a cell adhesion molecule..……….…………..………13 
 
Figure 5: Hypothesized role of IL17Ra in the cell aggregation assay. …………………....……14 
 
Figure 6: Hypothesized role of IL17Ra in the neurite outgrowth assay.………………...……...16 
 
Figure 7: Hypothesized role of IL17Ra in the artificial synapse formation assay..……………..17 
 
Figure 8: Schematic of cell aggregation assay protocol..………………………………………..19 
 
Figure 9: In the absence of ligand IL-17, overexpression of IL17Ra in HEK293 cells inhibits 
cell aggregation………………....………………………………..……………………………….21 
 
Figure 10: Long-term treatment of ligand IL-17 suppresses inhibition of cell aggregation.,...….23 
 
Figure 11: Long-term exposure to IL-17 suppresses inhibition of cell aggregation in IL17Ra 
overexpressing HEK293 cells.….....…..……………………………………………………….....24 
 
Figure 12: A proposed model for the role of IL17Ra in the cell adhesion………………...……27 
 
Figure 13: Schematic of morphology assay protocol....……………………………….………...30 
 
Figure 14: Treatment of ligand IL-17 increases neurite outgrowth in wild type primary cortical 
neurons.…………………………………………………………………………..………………31 
 
Figure 15: IL17Ra loss-of-function results in increased neurite outgrowth..….…………….….32 
 
Figure 16: A proposed model for the role of IL17Ra during neurite outgrowth and axon 
pathfinding…………………………………………………………………………...…………..35 
 
Figure 17: Schematic of synapse puncta count assay protocol.……………………………...….37 
 
Figure 18: Treatment of ligand has no effect on LacZ KD wild type primary cortical neurons, 
but suppresses puncta formation in IL17Ra KD neurons..……………………………………….38 
 
 v 
Figure 19: IL17Ra loss-of-function in wildtype primary cortical neurons inhibits synapse puncta 
formation when treated with ligand………......………………………………….……..………...39 
 
Figure 20: Schematic of artificial synapse formation assay protocol.…………………………..41 
 
Figure 21: Synapse formation is inhibited when IL17Ra is overexpressed in non-neuronal 
cells.....……………………………………………………………………………………………42 
 
Figure 22: Synapse formation in maternal immune activated (MIA) primary cortical neurons is 
impaired..…....………....…………………………………………………………………...…….43 
 
Figure 23: A proposed model for the role of IL17Ra during synapse formation..……………...46 
 
Figure 24: The potential role of IL17Ra during cortical development………………………….48 
 
Supplemental Figure 1: HEK293 cells and primary cortical neurons endogenously express 
similar levels of IL17Ra………………………………………………………………………….54 
 





















CHAPTER 1: INTRODUCTION 
 
Autism spectrum disorder (ASD) and its etiology 
Autism spectrum disorder (ASD) is a common neurodevelopmental disorder that is 
clinically characterized by social impairments, communication delay, and stereotypical repetitive 
behaviors (1). This disorder affects approximately 1 percent of the world population and has 
been reported in all socioeconomic and ethnic groups (2, 3). In the United States alone, ASD 
affects more than 3.5 million lives, and ASD services for U.S. citizens are estimated to cost 
$236-262 billion annually (4). It is critical to further elucidate the causes, potential therapeutic 
treatments, and preventative methods of the disorder to better treat the large population of 
individuals affected with ASD. 
The etiology of ASD is heterogeneous – that is, both genetic and environmental factors 
contribute to its pathogenesis (5). For example, numerous studies have reported strong genetic 
contributions to the cause of ASD. First, approximately 10% of individuals affected with ASD 
also display symptoms of other genetic, neurologic, or metabolic disorders, such as fragile X 
syndrome and tuberous sclerosis, revealing genetic associations between ASD and various 
disorders (6, 7).  In addition, the risk of ASD in newborns is 25 times greater than that in the 
general population if their siblings are affected with ASD, which strongly marks genetics as one 
of the root causes of ASD (8). Furthermore, two different twin studies revealed that identical 
twins have 60-90% concordance rate of ASD, compared to 0-24% in fraternal twins (9, 10). 
Finally, although more than 20 different chromosomes have autism loci, these only account for 
the subset of ASD population with other genetic syndromes, and not those with only ASD, 
implying ASD is multifactorial (6). 
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Alarmingly, the occurrence of ASD in the world has been sharply increasing over the 
past two decades. From 1992 to 2007, the estimated rate of incidence of ASD in the U.S. 
increased from 1 in 500 children to 1 in 110 children. In 2015, ASD was recently estimated to 
affect 1 in 45 children (11, 12). Other childhood immunological disorders, such as asthma, life-
threatening food allergies and autoimmune disorders, have reached epidemic levels in parallel to 
the increase in ASD (13). It is unlikely that the significant upward trends in these diseases can be 
attributed solely to genetics, as two decades is not nearly enough time for genetic changes to 
have a severe impact on the prevalence of various disorders at the population scale (14). 
Although the apparent increase in prevalence of these diseases may, in part, be attributed to 
heightened awareness, increase in knowledge, and the broadening of diagnostic criteria of the 
disorders, it has been hypothesized that environmental factors may have much greater roles on 
the pathogenesis of ASD than previously expected (11).  
Consistent with this idea, many recent studies attribute the cause of the rapid increase in 
individuals with ASD today to the rise in environmental stressors during critical periods of 
neurodevelopment, especially in genetically vulnerable individuals (15). More specifically, 
immune disturbance due to various environmental factors like psychological stressors, chemical 
exposures, and pharmaceuticals are candidate risk factors of ASD, as these factors may 
ultimately alter the maternal immune responses during prenatal development and detrimentally 
affect neurodevelopment (11).  
 
Maternal immune activation (MIA) 
Maternal immune activation (MIA) refers to the activation of the immune system in the 
mothers during gestation due to immune-related disruptions such as bacterial and viral infections. 
Many epidemiological studies emphasize the role of MIA in the pathogenesis of ASD. For 
 3 
example, the correlation between ASD and maternal viral infection during gestation was first 
noted when the number of individuals affected with ASD escalated from 0.05% to 8-13% after 
the 1964 rubella pandemic (16). More recently, an epidemiological study of over 10,000 records 
in the Danish Medical Birth Register revealed a strong correlation between prenatal infections in 
the mothers during their first and second trimesters of pregnancy, and a nearly threefold increase 
in frequency of ASD in their children born from those pregnancies (17). The results from these 
studies suggest the high likelihood of immune molecules playing critical roles in the 
pathogenesis of ASD.  
Although the specific mechanisms by which infections cause latent pathology in the 
central nervous system of the offspring are still unknown, previous research has reported that 
MIA and the maternal pro-inflammatory cytokine, rather than direct infection of the fetus, 
interfere with fetal neurodevelopment to induce ASD phenotypes (18). Accordingly, a study 
showed direct alterations in the concentrations of various maternal cytokines in relation to 
diagnosis of ASD in the children later in life. More specifically, the results showed that mothers 
who had borne children with ASD had increased mid-gestational levels of cytokines interleukin 
(IL)-4, IL-5, and interferon-gamma (IFN-gamma), compared to mothers who had not (19). An 
epidemiological study of the Danish Historic Birth Cohort also revealed increased concentrations 
of IL-4 and IL-5 in the amniotic fluids of the mothers that gave birth to children affected with 
ASD after, but not before, 1993. Although this contrast may be due to improvements in 
diagnostic criteria and is difficult to explain, the overall conclusions still imply that cytokines are 
critically involved in the pathogenesis of ASD (20). Together, these studies suggest that MIA 
during prenatal development can have deleterious effects on proper brain development, and 
ultimately on cognitive skills in the offspring. More specifically, the strong association between 
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MIA in pregnant mothers and ASD in the children born from these pregnancies implies that the 
changes in concentrations of cytokines that facilitate the maternal immune responses may be 
detrimental to neurodevelopment in the subsequent generation (18, 21). 
 
Cross-talk between the mother and embryo 
 
The exact mechanism by which the increased cytokine levels in the mothers after 
immune challenges affect brain development and behavior is still not well understood. However, 
we can hypothesize how certain immune molecules may cross the barrier to affect 
neurodevelopment, since the development of the maternal fetal exchange system, or utero-
placental circulation system, is well characterized. Upon implantation of the fertilized ovum, 
establishing proper connections to the mother is a critical step for the development of the embryo 
(22). At this stage, however, the embryo receives its necessary nutrients via simple diffusion. As 
the pregnancy proceeds, the utero-placental circulation system develops to control and regulate 
gas and nutrient exchange between the mother and the embryo. Placenta, an autonomous and 
transient organ, is formed during pregnancy and is responsible for physically connecting the 
embryo to its mother and facilitating maternal-embryonic exchange (23). The development of 
placental structures results in physical and functional connections, which facilitate hormonal 
regulations that direct the changes in the uterus and establish a hybrid vasculature system by 
which maternal blood transports material such as cytokines, nutrients, and gases to the embryo 
(22, 23).  
During the first trimester of the pregnancy, the endothelium of the placental villus 
differentiates and forms a placental barrier that regulates maternal-embryonic exchange. By the 
end of first trimester, the placental barrier consists of four layers that the gases, nutrients, and 
waste of the maternal and fetal blood must diffuse through (24). The embryo grows rapidly, and 
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during the second trimester, the endothelium of the villus adapts to this growth by dividing 
further. As a result, the endothelium of the villus becomes very thin, and the intervillus space 
between the maternal and fetal blood decreases. It is important to note that the maternal and fetal 
blood rarely come into contact, (though some cases of direct exchange have been observed), and 
molecules that are transferred to the fetus, and vice versa, are very carefully modulated (25). 
However, by this point of the second trimester, various molecules can relatively easily cross the 
placental barrier because the placental precursors are mono-layered and thin, compared to later in 
placental development (third trimester), when the barrier differentiates further and becomes more 
selective (26). It is believed that it is during the second trimester that the embryo is most 
susceptible to MIA, and this could possibly explain the high correlation of viral/bacterial 
infections during the second trimester of pregnancy in the mother with ASD in the offspring.  
 
Maternal immune activation (MIA) rodent models 
Since the establishment of maternal infection as a candidate risk factor for ASD, MIA has 
been modeled in rodents to better understand the neural basis of MIA-induced ASD deficits (27). 
Several rodent models of MIA have been created by maternal injections of either 
polyinosine:cytosine [poly(I:C)] or lipopolysaccharide (LPS) to induce the adverse 
transformations during brain development (27). Poly(I:C) is a synthetic double-stranded RNA 
that mimics the acute phase response of viral infections in the absence of the pathogen. Upon 
intraperitoneal injection, poly(I:C) targets maternal toll-like receptor (TLR) 3 of dendritic cells, a 
type of cell in the immune system, and activates downstream pathways to mimic the maternal 
immune response (28). In the second MIA rodent model, LPS, which is introduced via 
intrauterine injection, targets TLR4 of dendritic cells to induce similar ASD-like behavioral 
abnormalities seen in offspring of poly(I:C)-injected mothers (27, 28). These MIA models have 
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been widely adopted and many studies have utilized these MIA animal models to reproduce the 
core symptoms of ASD (29).  
MIA models help elucidate the roles of certain cytokines involved during maternal 
immune responses, as well as the implications of their elevated levels in causing ASD-like 
phenotypes (28). For example, a recent study of a pro-inflammatory cytokine IL-6 showed that 
IL-6 alone is necessary and sufficient to induce ASD-like neuropathological and behavioral 
changes in the MIA offspring of dams. More specifically, MIA-induced ASD-like phenotypes 
were eliminated when IL-6 was blocked in the mothers, and IL-6 exposure during gestation in 
the absence of poly(I:C) MIA induction was sufficient to cause ASD-like phenotypes in the 
offspring. This study strongly suggests the central role of MIA in causing long-term, ASD-like 
neuropathological and behavioral changes in the offspring (18). 
 
T helper (Th) 17 / IL-17 pathway 
Although the necessity of maternal cytokine IL-6 in the induction of ASD-like 
phenotypes is well recognized, the exact immune cell populations responsible for the induction 
of ASD-like cortical and behavioral phenotypes in the fetus have not been identified (18). 
Several studies recognize the downstream mediators of IL-6, Th17 cells and its corresponding 
cytokine IL-17, as the candidate immune cell population and molecule responsible for the 
pathogenesis of ASD in the offspring. First of all, Th17 cells have been known to play a role in 
the induction of inflammatory and autoimmune diseases such as asthma, rheumatoid arthritis, 
psoriasis, inflammatory bowel disease and multiple sclerosis, suggesting the central role of the 
Th17/ IL-17 pathway in causing various immune-related diseases (30). A recent study revealed 
that the concentration of IL-17a, which is secreted by Th17 cells, is increased in the sera of a 
group of ASD children, and a genome-wide copy number variant (CNV) analysis of ASD 
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patients revealed that il17a is enriched and dysregulated (31, 32). These data all suggest that the 
Th17 cells and their cytokines may be the candidate immune cell population and molecules that 
directly affect neurodevelopment of the offspring and therefore induce ASD. Further 
characterization of the Th17/ IL-17 signaling pathway would allow better understanding of the 
molecular basis of how ASD-like behavioral deficits are induced via MIA.  
Most recently, the Choi lab at the Massachusetts Institute of Technology has identified 
the cellular source that is responsible for causing ASD-like cortical and behavioral phenotypes in 
the offspring of the MIA model. More specifically, we showed that IL-17 is necessary and 
sufficient to induce ASD-like phenotypes (33). We found that IL-17a levels in maternal sera are 
elevated upon poly(I:C) injection, and that pre-treatment of mothers with antibodies blocking IL-
17a before injection restores elevated cytokine levels (Fig. 1A). Importantly, we also found 
elevated IL-17Ra mRNA levels in fetal brains at E14.5 in fetus of mothers injected with 
poly(I:C), suggesting that maternal IL-17 directly enters and amplifies the signaling in the fetal 
brain (Fig. 1B).  Furthermore, abnormal cortical development was observed in affected fetus at 
E14.5, as shown by decreased levels of SATB2 expression levels, a marker of postmitotic 
neurons in superficial cortical layers. This abnormality was rescued by inhibition of IL-17a 
signaling via pre-treatment with antibodies (Fig. 1C). Finally, abnormal cortical morphology was 
observed in afftected fetus at E18.5, and was rescued when the mothers were pre-treated with 
antibodies blocking IL-17a (Fig. 1D). These results together not only suggest that the Th17 
cell/IL-17 pathway is involved in inducing ASD-like phenotypes, but also show that IL-17 can 
directly affect neurodevelopment and induce adverse cortical transformations in the fetal brain to 







Figure 1: MIA-induced mothers express elevated IL-17a levels, leading to elevated IL-17Ra 
mRNA levels and abnormal cortical development in the offspring. (A) Serum concentrations 
of maternal IL-17a at E14.5 in PBS (control) or poly(I:C)-injected mothers, pretreated with 
isotype control or IL-17a blocking antibodies. (B) In situ hybridization with an IL-17Ra RNA 
probe in E14.5 fetal brains derived from PBS- or poly(I:C)- injected mothers. (C) 
Immunofluorescence staining of SATB2 (a marker of postmitotic neurons in superficial cortical 
layers) in E14.5 fetal brain, derived from PBS- or poly(I:C)-injected mothers, pretreated with 
isotype control (Cont) or IL-17a blocking antibodies (anti-IL-17a). Scale bar represents 100m. 
(MZ: marginal zone, CP: cortical plate, SP: subplate, SVZ: subventricular zone, VZ: ventricular 
zone) (D) SATB2 and TBR1 (a marker restricted to deeper cortical layers) staining in E18.5 fetal 
brains from animals treated as in (C). Adapted from Choi et al., 2016. 
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According to Choi et al., inflammation in the mother results in upregulation of pro-
inflammatory cytokines, such as IL-6, which target and induce differentiation of Th17 cells in 
the mother’s circulating blood. Subsequently, IL-17 cytokines are expressed, which migrate 
across the placenta via maternal endometrial and umbilical vessels and induce IL-17Ra 
expression, as well as abnormal cortical phenotype in the fetal brain. This dysregulation of 
cytokine concentrations may explain the behavioral abnormalities observed in the MIA-induced 
ASD-like offspring (Fig. 2) (33). The specific role of IL17Ra and its molecular consequences, 











Figure 2: The proposed mechanism by which the maternal Th17/IL-17 pathway induces 
MIA-dependent behavioral and cortical abnormalities in the offspring. Based on mouse 
experiments, maternal cytokine IL-6 levels increase upon inflammation. IL-6 targets and initiates 
differentiation of Th17 cells, which produce IL-17a. IL-17a travels through the selective 
placental barrier via maternal endometrial and umbilical vessels, and Il17Ra expression in the 
fetal brain is increased. The increase of IL17ra results in amplified IL-17 signaling in the fetal 
brain, and leads to ASD-like cortical and behavioral phenotypes in the offspring. Adapted from 
Choi et al., 2016. 
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As previously stated, recent studies show that both concentrations of maternal IL-6 and 
its downstream mediator IL-17 are elevated, and that either cytokine is necessary and sufficient 
to cause ASD-like phenotypes in the offspring (18, 33). These results raise the question of which 
cytokine directly affects the offspring and is responsible for inducing ASD-like phenotypes. In 
order to determine the specific immune molecule that is at play, we directly injected either IL-6 
or IL-17 into the fetus and observed its effects on neurodevelopment. Only the IL-17 injected 
fetal group displayed MIA-induced ASD-like phenotypes, indicating that although IL-6 and IL-
17 both mediate the maternal immune response, the placenta-blood barrier is selective and only 
IL-17 was able to penetrate into the fetal brain to directly affect neurodevelopment (unpublished 
data). Further studies of the IL-17 pathway are needed to elucidate the molecular mechanisms by 
which IL-17 signaling adversely affects neurodevelopment in the fetus. 
 
MIA, neurodevelopment, and ASD 
Abnormalities of cortical phenotype in the MIA offspring suggest that MIA disrupts 
normal cortical development during the critical period of brain development. The period of 
corticogenesis in mice (E11-19) overlaps with the time period during which the fetus is most 
susceptible to the actions of MIA (33, 34). Cortical development encompasses the entire process 
of proliferation, migration, differentiation, synaptogenesis, myelination, gliogenesis, and 
apoptosis of neural cells, indicating multiple time points at which proper neurodevelopment can 
be disrupted. Throughout the entire process of cortical development, cytokines play critical roles 
in regulating the intercellular interactions during development and functioning of the cortical 
layers (35). 
In neocortical development, proliferation first begins by symmetrical division of the 
neuroepithelial cells in the ventricular zone. Then, these precursor cells become radial glial cells, 
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which are multipotent progenitors of neural cells, and either serve as expanding cells with 
processes that the neural cells migrate along, or become neurogenic cells (35, 36). Newborn 
neurogenic cells migrate along the radial glial processes, and arrive in their correct layers in an 
inside-out manner, with earlier born cells populating the deeper layers of the cortex, and later 
born cells populating the superficial layers of the cortex. Upon arrival, the cells differentiate and 
form complex neural circuitry that underlies the function of the cortices. Furthermore, microglia, 
or immune surveillance cells with hematopoietic origin, play critical roles during development 
by clearing apoptotic debris and modulating vascularization, survival and synapse formation and 
function, in part through their response to, and secretion of, various cytokines (37). A small 
subclass of cytokines regulates these corticogenic processes. For example, IL-1 is known to 
regulate proliferation of progenitor cells, while IL-6 and IL-10 are thought to regulate 
oligodendrocyte and astrocyte maintenance to ultimately facilitate neuronal growth (37). These 
processes overlap with periods in which the fetus is most vulnerable, and the dysregulation of 
cytokine concentrations, and consequently disruption of proliferation, migration, or 
differentiation, will most likely result in abnormal cortical development (35, 37). 
Based on previous studies, as well as our preliminary data, here we propose the possible 
mechanism by which the IL-17a pathway disrupts proper migration, axon pathfinding and 
synapse formation during cortical development to induce abnormal cortical and behavioral 
phenotypes. More specifically, we hypothesize that IL-17Ra acts as a cell adhesion molecule 
during cortical development due to several reasons. First, IL17Ra’s topology is homologous to 
other well-characterized cell adhesion molecules, many of which have extracellular, 
transmembrane, and intracellular domains (38). Furthermore, the extracellular domain of the 
protein has a fibronectin type III (FNIII) domain, which is well known to be involved in various 
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processes during neurodevelopment, such as cell adhesion, migration, and morphogenesis (Fig. 3) 
(39). Additionally, it is worthwhile to note that many well studied cell adhesion molecules like 
neural cell adhesion molecule (NCAM), synaptic cell adhesion-like molecule (SALM), and 
roundabout (Robo) also express FNIII domains. Finally, it is important to note that different sets 
of cell adhesion molecules regulate different neurodevelopmental processes, and thus it is 
important to conduct many assays to determine the specific role of the protein (40). For example, 
another cytokine of the interleukin family, IL-1, is known have adhesive properties and play 
active roles during brain development. Its receptor, IL-1RAcP, was found to act directly as a cell 
adhesion molecule that organizes neuronal synaptogenesis. Interestingly, the intracellular domain 
of IL17Ra has a SEFIR domain, which is similar in length and secondary structure as the 
toll/interleukin-1 receptor (TIR) domain of the IL-1RacP (Fig. 3) (39, 41). Based on previous 
studies and the homology between IL17Ra and other well-characterized cell adhesion molecules, 










Figure 3: Topology of IL17Ra.  IL17Ra has extracellular, transmembrane, and intracellular 
domains. The extracellular domain of IL17Ra has a fibronectin type III (FNIII; purple) domain, 
and the intracellular domain has a SEFIR domain (light brown). 
 13 
Thesis aims 
Here, we aim to test whether IL17Ra, a cognate receptor of IL-17, is an adhesion 
molecule that facilitates various neurodevelopmental processes such as neurite outgrowth, axon 
pathfinding, and synapse formation, and if so, we will attempt to determine which of these 
processes the protein facilitates. If IL17Ra has an indirect role in cell adhesion, activation of 
IL17Ra will lead to activation of downstream pathways that will stimulate the action of other 
endogenous cell adhesion molecules (Fig. 4A). If IL17Ra has a direct role in cell adhesion, 
activation of IL17Ra itself will stimulate cell adhesion via homophilic binding to itself or via 
heterophilic binding to other endogenous cell adhesion molecules (Fig. 4B). Although further 
experiments are required to determine the exact mechanisms, if IL17Ra acts as a cell adhesion 
molecule, either case would lead to increased facilitation of cell adhesion, and therefore 
increased cell aggregation and synapse formation.  
 
Figure 4: The potential role of IL17Ra as a cell adhesion molecule. The diagram illustrates 
the indirect (A) and direct (B) mechanism by which IL17Ra may act as a cell adhesion molecule 
to facilitate cell adhesion. 
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In order to test this hypothesis, we will use four different assays – cell aggregation assay, 
neurite outgrowth assay, synapse puncta assay, and artificial synapse formation assay. 
 
1. Cell Aggregation Assay 
The cell aggregation assay aims to determine whether IL17Ra can facilitate stable cell-to-
cell interactions by transfecting IL17Ra onto human embryonic kidney 293 (HEK293) cells. In 
HEK293 cells with endogenous levels of IL17Ra (control group), some level of aggregate will 
form due to endogenous adhesion molecules and IL17Ra (Fig. 5A). However, if IL17Ra is a cell 
adhesion molecule, HEK293 cells overexpressing IL17Ra will form larger aggregates than cells 
that do not (Fig. 5B). On the same note, the presence of IL-17 will induce even greater cell 






Figure 5: Hypothesized role of IL17Ra in the cell aggregation assay. (A) IL17Ra transfected 
HEK293 cells, in addition to endogenous adhesion molecules will form larger aggregates than 
(B) mock vector transfected HEK293 cells with endogenous adhesion molecules and IL17Ra 
only. (C) The addition of IL-17, the ligand of IL17Ra, will facilitate IL17Ra adhesion and induce 







2. Neurite Outgrowth Assay using primary cultured neurons 
 
One primary function of neuronal cell adhesion molecules is to regulate axon growth (42). If 
IL17Ra were a potential cell adhesion molecule, one role of the protein may be to aid neurite 
outgrowth. Therefore, upon loss of function of IL17Ra, we would expect to see impaired neurite 
outgrowth in primary cortical neurons. Although in vitro assays clearly have advantages, such as 
having greater control over the environmental conditions and the ability to observe homogeneous 
populations of cells that undergo uniform and synchronous changes, it is important to note that 
the inherent complexity of in vivo systems is lost. Nevertheless, primary neuronal cultures are a 
powerful tool for analyzing molecular mechanisms by which neuronal development proceeds, 
and these cultures are commonly used to study various aspects of neuronal development. It is 
worthwhile to note that many studies have revealed that primary cortical neurons are good 
representations of in vivo neurons in various aspects of neuronal morphology, such as having 
long processes, maturation, aging, decreased proliferation rates, and death (43). Here, we will 
utilize in vitro systems of primary cortical neuron cultures to genetically manipulate and 
characterize the role of IL17Ra in cortical neuron development.  
CRISPR/Cas9 is a genome editing technique that allows easy and specific control of gene 
expression. We will knockdown endogenous IL17Ra expression in primary neuron culture from 
the cortex of wildtype fetus using the CRISPR/Cas9 technique, to analyze whether IL17RA loss-
of-function affects morphogenesis of primary cultured neurons. We hypothesize that in the LacZ 
KD control neurons with endogenous IL17Ra expression level,  IL17Ra will act as a cell 
adhesion molecule to aid the process of neurite outgrowth (Fig. 6A). On the other hand, in the 
IL17Ra KD neurons with IL17Ra loss-of-function, we hypothesize that neurite outgrowth will be 













3. Primary Cultured Neuron Synapse Puncta Assay 
We will use the CRISPR/Cas9 genome editing technique to also examine the effects of 
IL17Ra loss-of-function on synaptogenesis of primary cortical neurons. We hyothesize that if 
IL17Ra acts as a cell adhesion molecule, the protein will aid the process of synapse puncta 
formation, and that the IL17Ra KD neurons will, therefore, show impaired synapse formation 





Figure 6: Hypothesized role of IL17Ra in the neurite outgrowth assay. (A) In neurons with 
LacZ KD, or endogenous IL17Ra expression, IL17Ra will aid in neurite outgrowth by adhering 
to the proteins in the extracellular matrix (ECM). (B) In neurons with IL17Ra KD, IL17Ra loss-
of-function will result in impaired neurite outgrowth. 
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4. Primary Cultured Neuron Artificial Synapse Formation Assay 
 
The artificial synapse formation assay tests whether IL17Ra overexpressing non-neuronal 
cells can form stable, synapse-like interactions with endogenous IL17Ra and cell adhesion 
molecules of primary cortical neurons. We will also repeat this procedure using primary cortical 
neurons from MIA offspring to assess the effects of IL17Ra overexpression in MIA neurons. If 
IL17Ra aids in synapse formation by acting as a synaptic cell adhesion molecule, we expect to 
observe increased levels of synapse formation between wild type neurons and IL17Ra 
overexpressing non-neuronal cells (Fig. 7A) compared to levels in control situations (Fig. 7B). In 
addition, in MIA neurons that are known to overexpress IL17Ra, we expect to observe further 
increase in synapse formation compared to that observed in wild type neurons (Fig. 7C). 
 
Figure 7: Hypothesized role of IL17Ra in the artificial synapse formation assay. (A) Wild 
type neurons with endogenous IL17Ra expression will exhibit certain level of synapse formation 
with IL17Ra-overexpressing non-neuronal cells. (B) If IL17Ra aids in synapse formation, in 
control situations, where the non-neuronal cells do not overexpress IL17Ra, synapse formation 
will be inhibited. (C) If IL17Ra aids in synapse formation, MIA neurons will exhibit increased 
synapse formation with IL17Ra-overexpressing non-neuronal cells, as MIA neurons overexpress 
IL17Ra as well. 
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We investigated the role of the cytokine receptor IL17Ra in cell adhesion using the cell 
aggregation assay. We observed cell aggregation in HEK293 cells for the following reasons: (i) 
Endogenous IL17Ra expression levels in primary cortical neurons and HEK293 cells are similar 
(Fig. S1); and (ii) Non-neuronal cell adhesion assays are simple and easily reproducible, yet very 
effective tests to test the adhesive properties of a protein of interest. 
This assay utilized HEK293 cells transfected with IL17Ra fused with CFP or YFP to 
assess whether overexpression of IL17Ra aids in cell adhesion.  After transfection, the cells were 
treated with the protease trypsin, and the calcium chelator EDTA, to dissociate and inhibit 
endogenous cell adhesion molecules. The dissociated cells were then treated with calcium 
chloride to aid endogenous cell adhesion, and incubated in the presence or absence of the 
protein’s ligand, IL-17.  Finally, the cells were imaged at 0 hour, 2 hours, 4 hours, and 24 hours 
upon incubation to determine the changes in cell adhesion, represented by the area of the cell 
aggregate. As comparison, the same procedures were repeated using HEK293 cells transfected 
with different mock vectors fused with fluorescent proteins (BFP or mCherry) (Fig. 8). The 
adhesive properties of IL17Ra were characterized by measuring and comparing the size of cell 
aggregation in IL17Ra-transfected cells to that of mock-vector transfected cells via percent 











Figure 8: Schematic of cell aggregation assay protocol. HEK293 cells were transfected with 
two fluorescently labeled IL17Ra (CFP or YFP). Trypsin, a protease, and EDTA, a calcium 
chelator, were added to break apart and inhibit endogenous cell adhesion molecules. The cells 
were then treated with calcium chloride, and incubated with or without the ligand, IL-17. The 
cells were imaged at various time points to assess the role of IL17Ra in cell adhesion, as well as 
the effects of the presence of absence of ligand. 
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IL17Ra overexpression inhibits cell aggregation in the absence of ligand 
In the absence of ligand (PBS treatment), both IL17Ra and blank-vector transfected cells 
showed time-dependent increases in cell aggregation (Fig. 9A). Quantification showed that 
IL17Ra overexpressing cells exhibited smaller % differences from baseline cell aggregation 
compared to those of blank-vector transfected controls after 2 hours, 4 hours, and 24 hours of 









































Figure 9: In the absence of ligand IL-17, overexpression of IL17Ra in HEK293 cells 
inhibits cell aggregation. The role of IL17Ra in cell adhesion was characterized by measuring 
the size of cell aggregation of HEK293 cells (outlined in white) transfected with IL17Ra (purple) 
or with blank vectors (orange) at various time points. (A) The percent difference from baseline 
(area of cell aggregates at 0 HR) was calculated to analyze the effect of IL17Ra in cell 
aggregation. Both groups of HEK293 cells incubated in the absence of ligands showed time-
dependent increases in cell aggregation. B. Upon quantification, cells transfected with IL17Ra 
formed smaller cell aggregates than cells transfected with blank vectors at 2, 4, and 24 hours of 
incubation. All bars represent mean + s.e.m. Unpaired t-test; **p<0.01, ***p<0.001, 
****p<0.0001. All images were taken at 10X. Cell aggregate sizes were measured using ImageJ. 
Scale bar indicates 30µm. 
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Long-term treatment of IL-17 blocks the inhibition of cell aggregation in IL17Ra 
overexpressing cells 
 
Both IL17Ra and blank-vector transfected cells showed time-dependent increases in cell 
aggregation in the presence of ligand (IL-17 treatment) (Fig. 10A). Similar to the cells incubated 
in the absence of ligand, IL17Ra overexpressing cells exhibited less cell aggregation compared 
to blank-vector transfected controls after 2 hours and 4 hours of incubation. However, after long-
term (24 hours) exposure to IL-17, this inhibition of cell aggregation was blocked, and the two 
















































Figure 10: Long-term treatment of ligand IL-17 suppresses inhibition of cell aggregation. 
The role of IL17Ra in cell adhesion was characterized by measuring and comparing the size of 
cell aggregation of HEK293 cells (outlined in white) transfected with IL17Ra (purple) or mock 
(orange) vectors. (A) The percent difference from baseline (area of cell aggregates at 0 HR) was 
calculated to analyze the effect of IL17Ra expression in cell aggregation. Both groups of cells 
transfected with IL17Ra or with blank vectors, incubated in the presence of ligands, showed a 
time-dependent increase in cell aggregation. B. Upon quantification, IL17Ra overexpressing 
cells formed smaller aggregates than those transfected with blank vectors upon short-term 
incubation (2 hr and 4 hr). Upon long-term incubation of 24 hr, the two groups showed equal 
amount of cell aggregation, and inhibition of cell aggregation was blocked. All bars represent 
mean + s.e.m. Unpaired t-test; *p<0.05, ****p<0.0001. All images were taken at 10X. Cell 
aggregate areas were measured using ImageJ. Scale bar indicates 30µm.  
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Inhibition of cell aggregation in IL17Ra overexpressing cells is blocked after long-term 
exposure to IL-17 
 
IL17Ra overexpressing cells incubated in the absence or presence of ligand for four hours 
exhibited smaller aggregate sizes than control cells (Fig. 11A). This pattern of inhibition, 
however, was blocked upon long-term exposure to the ligand, and IL17Ra overexpressing and 













Figure 11: Long-term exposure to IL-17 suppresses inhibition of cell aggregation in IL17Ra 
overexpressing HEK293 cells. The role of IL17Ra in cell adhesion was characterized by 
measuring and comparing the size of cell aggregation of HEK293 cells transfected with IL17Ra 
(purple) or blank vectors (orange) in the absence or presence of ligand IL-17. (A) Upon 4 hours 
of incubation, IL17Ra expression inhibited cell aggregation, as shown by the decrease in cell 
aggregate size of IL17Ra overexpressing cells. (B). Upon 24 hours of incubation, PBS treated 
IL-17Ra overexpressing cells formed smaller aggregates compared to the aggregates observed 
among PBS treated control cells, IL-17 treatment, however, blocked this pattern of inhibition, 
and the two groups showed similar levels of aggregation. All bars represent mean + s.e.m. One-
way ANOVA; ***p<0.001, ****p<0.0001. Cell aggregate areas were measured using ImageJ.  
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Discussion 
Maternal IL-6 concentrations increases upon inflammation, which results in increased IL-
17 concentrations (18, 33). Although the mechanism is still unknown, maternal IL-17 is thought 
to travel to the fetus to induce increased expression of IL17Ra. The increased expression of 
IL17Ra then amplifies IL-17 signaling in the fetus, which adversely impacts neurodevelopment 
of the fetus and causes abnormal cortical and behavioral ASD-like phenotypes (33). Here we 
attempt to elucidate the role of IL17Ra during development by characterizing its adhesive 
properties. Our results from the cell aggregation assay indicate that IL17Ra acts as a protein with 
inhibitory roles in cell adhesion. 
The purpose of the cell aggregation assay was to determine whether IL17Ra acts as a cell 
adhesion molecule to stimulate cell adhesion among HEK293 cells that overexpress the protein. 
Contrary to our hypothesis, our results indicated that IL17Ra expression in HEK293 cells 
inhibits cell adhesion. When IL17Ra expressing HEK293 cells were incubated in the absence of 
its ligand IL-17, lower levels of cell aggregation were observed compared to those of control 
cells (Fig. 9). On the other hand, when IL17Ra expressing HEK293 cells were incubated with its 
ligand IL-17, lower levels of cell aggregation were observed only upon short-term exposure to 
IL-17 (2 and 4 hr), and this inhibition was blocked upon long-term exposure (24 hr) (Fig. 10). 
Further analysis confirmed lower levels of cell aggregation in IL17Ra overexpressing cells 
incubated in the absence of ligand, and restored, control levels of cell aggregation in IL17Ra 
overexpressing cell incubated with its ligand (Fig. 11). Together, these results suggest that the 
expression of IL17Ra in HEK293 cells disrupts stable cell-cell interactions and inhibits cell 
aggregation.  
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One may argue that the lower levels of aggregation in IL17Ra are due to lower 
transfection efficiency of the IL17Ra, as well as the lower intensities of fluorescence. However, 
this can be accounted by the high sample size, as well as the high number of replicate studies. To 
further confirm our results, we will re-conduct this assay in a more controlled manner and 
normalize the assay to the number of single cells remaining instead. For example, one may argue 
that using cell aggregate area as a measure of cell aggregation is not very accurate because this 
method fails to account for the 3-dimensional aspect of cell aggregation. Instead, we will count 
the number of single cells remaining at each time point in our next set of experiments. In 
addition, since this cell aggregation assay was aimed towards defining IL17Ra’s role as a 
potential cell adhesion molecule in aiding cell aggregation, but our results hint at a potential 
inhibitory role of IL17Ra, we will redesign the assay to test its inhibitory characteristics. For 
example, we will co-transfect non-neuronal cells with IL17Ra, as well as a well-characterized 
cell adhesion molecule, and compare the level of cell aggregation to that of cells transfected with 
IL17Ra only to observe whether the cells co-transfected with IL17Ra exhibit a pattern of 
inhibition in cell aggregation. 
Based on our results, here we propose a model in which IL17Ra plays an inhibitory role 
in cell adhesion. IL17Ra has a binding partner, which upon binding destabilizes the interaction 
and leads to less cell adhesion (Fig. 12B). Furthermore, this model also explains why the 
introduction of IL-17 can block the inhibition that occurs in the presence of IL17Ra. In the 
presence of its ligand, IL17Ra will bind to IL-17 instead, and therefore block the inhibition of 
cell adhesion that normally occurs in the absence of its ligand (Fig. 12C).  
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This now raises the question, whether or not IL17Ra has other binding partners to 
mediate changes in cell adhesion, as well as what specific domain of the protein is responsible 
for bringing about these changes. Future studies will include co-transfecting the cells with a 
well-characterized cell adhesion molecule and IL17Ra to confirm inhibition in cell aggregation, 
using pull-down assays to isolate the binding partners of IL17Ra, using mass spectrometry to 
identify the binding partners, as well as transfecting truncated forms of IL17Ra to determine the 
domain responsible for inhibitory changes. Although cell aggregation assay uses HEK293 cells 
and therefore is not directly translatable to neurodevelopment, this model allows for identifying 
independent contributions of IL17Ra in cell adhesion. Furthermore, HEK293 cells are very 
Figure 12: A proposed model for the role of IL17Ra in cell adhesion. (A) When control non-
neuronal cells are incubated in the absence of ligand, the cells will exhibit a certain level of cell 
adhesion. (B) When non-neuronal cells overexpressing IL17Ra are incubated in the absence of 
ligand, IL17Ra will bind to other cell adhesion molecules to destabilize the interaction between 
the cells. (C) However, when the ligand is introduced, IL17Ra has a higher affinity to its ligand 
than to other endogenous cell adhesion molecules, therefore blocking inhibition that occurred in 
the absence of ligand. 
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stable cell lines that allow us to easily renew and reproduce more cells for future studies. With 
results from this assay, we may soon be able to accurately confirm whether or not IL17Ra has 




































We next examined the role of cytokine receptor IL17Ra in the morphogenesis of wild 
type cortical neurons in vitro by analyzing their neurite development. We observed neurite 
outgrowth in primary cortical neurons for the following reasons: (i) in vitro experiments allow 
greater control of environment and manipulation of genome; (ii) Cell adhesion molecules are 
known to regulate morphogenesis of cortical neurons; (iii) Abnormal corticogenesis has been 
implicated in many MIA models, as well as in human studies (33, 44). 
In order to test this, we compared the neurite outgrowth lengths in neurons with 
endogenous IL17Ra expression and with IL17Ra KD to measure the effect of IL17Ra loss-of-
function. In preparation of the primary neuronal morphology assay, wild type primary cortical 
neurons were plated, and at days in vitro (D.I.V.) 4, LacZ or IL17Ra was knocked-down using 
the CRISPR/Cas9 technique. LacZ (endogenous IL17Ra expression levels) or IL17Ra (IL17Ra 
loss-of-function) knockdown was confirmed visually, as Cas9 transduction was indicated by 
GFP fluorescence, and via SURVEYOR nuclease assay (Fig. S2). Furthermore, these two groups 
were grown either in the absence (PBS treatment) or the presence of ligand (IL-17 treatment), 
and fixed and imaged at D.I.V.13. (Fig. 13A). The images taken at D.I.V. 13 were then analyzed 























Figure 13: Schematic of morphology assay protocol. (A) Primary cortical neurons from wild 
type animals were plated and grown for 4 days. At days in vitro (D.I.V.) 4, the genomes of the 
cells were edited using the CRISPR/Cas9 editing technique. Then, the cells were grown in the 
absence (PBS treatment) or the presence (IL-17 treatment) for 9 more days. Cells were fixed at 
D.I.V. 13 and stained. (B) The imaged cells were analyzed for neurite outgrowth using ImageJ. 
Neurite length between two cell bodies was measured for each group and treatment type, and 
the mean values were compared. All images were taken at 30X magnification. Scale bar is 
indicative of 50µm. 
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Treatment of ligand IL-17 increases neurite outgrowth in wild type primary cortical 
neurons  
 
 In wild type primary cortical neurons with LacZ KD, treatment with IL-17 resulted in 
approximately 1.8 times longer neurite outgrowth than those grown in the absence of ligand (Fig. 
14A). Similarly, treatment of IL-17 resulted in approximately 1.6 times longer neurite outgrowth 




























Figure 14: Treatment of ligand IL-17 increases neurite outgrowth in wild type primary 
cortical neurons. Neurite outgrowth of wild type primary cortical neurons with LacZ KD 
(purple) or IL17Ra KD (orange) was measured. (A) IL-17 treated LacZ KD neurons showed 
longer neurite outgrowth than control neurons. (B) Similarly, IL-17 treated IL17Ra KD neurons 
showed longer neurite outgrowth than control neurons. All bars represent mean + s.e.m. 
Unpaired t-test; **** p <0.0001.  
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IL17Ra loss-of-function in wild type primary cortical neurons increases neurite outgrowth 
 
Quantification showed that IL17Ra neurons grown in the absence of IL-17 exhibit 
approximately 1.3 times longer neurites than LacZ neurons grown in similar conditions (Fig. 
15A). Although treatment of IL-17 resulted in increases in neurite outgrowth in both LacZ KD 























Figure 15: IL17Ra loss-of-function results in increased neurite outgrowth. Neurite 
outgrowth of wild type primary cortical neurons with LacZ KD (purple) or IL17Ra KD (orange) 
was measured. (A) Neurons with IL17Ra loss-of-function showed increased neurite outgrowth in 
the absence of ligand. (B) Neurons with IL17Ra loss-of-function showed further increase in 
neurite outgrowth upon IL-17 treatment, compared to neurons with endogenous IL17Ra 
expression. All bars represent mean + s.e.m. Unpaired t-test; **p<0.01, ****p <0.0001.  
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Discussion 
 The purpose of the primary cultured neurite outgrowth assay was to determine the effects 
of IL17Ra loss-of-function on the morphogenesis, specifically on neurite outgrowth, of primary 
cortical neurons. Contrary to our hypothesis that the cytokine will only induce growth in control 
neurons with endogenous IL17Ra expression, both control and IL17Ra KD groups exhibited 
increases in neurite outgrowth when treated with cytokine IL-17 (Fig. 14). Furthermore, contrary 
to our hypothesis that IL17Ra loss-of-function will suppress neurite outgrowth, neurite 
outgrowth increased in both endogenous IL17Ra expressing and IL17Ra KD neurons, and this 
growth was further amplified in the IL17Ra KD group (Fig. 15). Together, these results show 
that cytokine IL-17 can induce neurite outgrowth even in the absence of its receptors. 
Furthermore, these results suggest that expression of IL17Ra leads to inhibition of neurite 
outgrowth, and upon KD, this inhibition is blocked to further induce neurite outgrowth. Although 
the neurotrophin-like role of IL-17 was unexpected, the inhibitory pattern of IL17Ra is consistent 
with our results from the cell aggregation assay. 
One may raise the question of reliability in knocking-down IL17Ra using the 
CRISPR/Cas9 genome editing technique. However, we have confirmed CRISPR/Cas9 KD 
efficiency using the SURVEYOR nuclease assay (Fig. S2), and also recently have generated a 
KO murine line to repeat and confirm our results. Future studies will involve using primary 
cortical neurons from IL17Ra KO mice instead of those with CRISPR/Cas9 KD to assure 
attribute results from our assays to IL17Ra loss-of-function. Furthermore, our result that neurite 
outgrowth was increased even in IL17Ra KD neurons hints at the possibility of the Th17/IL-17 
signaling pathway having normal physiological functions during brain development. Further 
supporting this notion, previous studies have observed structural similarities between the family 
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of IL-17 cytokines and neurotrophic factors (e.g. nerve growth factor) (45, 46). Interestingly, 
these results suggest the possibility of cross-talk between the IL-17 and neurotrophic factor 
signaling pathways to mediate normal development. On the same note, during normal cortical 
development, it is important for the axons to be able to adhere to various classes of adhesion 
molecules. It is also crucial to be able to detach, instead of adhere, by downregulating and/or 
inhibiting of cell adhesion molecules. For example, changes in cell adhesion molecule activity 
are critical in order to pioneer new directions of neurite outgrowth and arrive at the desired 
location (47). In order to further elucidate the mechanism by which IL17Ra facilitates neurite 
outgrowth and axonal pathfinding, we will conduct a neuronal migration assay that utilizes tissue 
sections and their neuronal migration patterns to examine the effects of IL-17 signaling on 
development. 
Previous findings have shown that MIA disrupts cortical development (33, 48). Based on 
our findings, here we propose a mechanism by which abnormal neurite outgrowth may occur. 
During axonal pathfinding, the inhibition of a set of cell adhesion molecules is required in order 
to change directions (40). IL17Ra may play an inhibitory role and downregulate cell adhesion to 
the extracellular matrix to suppress neurite outgrowth (Fig. 16A). In neurons with IL17Ra KD, 
this inhibition is blocked, and we may observe increases in cell motility and neurite outgrowth 
(Fig. 16B).  On a similar note, IL17Ra may play an inhibitory role and suppress cell adhesion 
molecules to guide axonal pathfinding during directional changes (Fig. 16C). On the other hand, 
when IL17Ra is overexpressed in the MIA model, too much inhibition may result in its inability 
to reach the desired destination, and abnormal/ overshoot of the neurite (Fig. 16D). It is 
important to keep in mind that this in vitro assay has limitations, as it is not fully representative 
of conditions in vivo. However, the advantages outweigh its limitations, as this in vitro model 
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allows us to identify independent contributions of IL17Ra in morphogenesis. With more 
experiments, we may be able to elucidate the mechanisms by which dysregulation of the IL17Ra 
signaling mechanism induces abnormal cortical development.  
 
Figure 16: A proposed model for the role of IL17Ra during neurite outgrowth and axon 
pathfinding. (A) IL17Ra normally inhibits adhesion to the extracellular matrix (ECM) that is 
required for neurite outgrowth. (B) Upon IL17RA loss-of-function, this inhibition is blocked, 
and neurite outgrowth increases. (C) During normal development, one set of cell adhesion 
molecules are needed to guide the axons to grow in a certain direction (navy). Inhibition of this 
set of cell adhesion molecules is needed (orange) via IL17Ra signaling, in order to detach and 
guide the axon towards the desired destination (red circle). (D) Upon IL17Ra loss-of-function, 
and therefore disruption of normal neurite outgrowth and axon pathfiding, the axon will continue 
growing, not only resulting in increased neurite outgrowth, but also abnormal cortical 
development. 
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In order to investigate the role of cytokine receptor IL17Ra in synapse formation, the 
puncta formation development in wild type primary cortical neurons was analyzed in vitro as 
another measure of morphogenesis.  
Specifically, we compared the synapse puncta count in neurons with endogenous IL17Ra 
expression and with IL17Ra KD to measure the effects of IL17Ra loss-of-function. Wild type 
primary cortical neurons were plated, and at days in vitro (D.I.V.) 4, the genomes of the cells 
were edited using the CRISPR/Cas9 technique. More specifically, the groups of comparison 
were primary cortical neurons with LacZ KD (endogenous IL17Ra expression) or IL17Ra KD 
(IL17Ra loss-of-function). Furthermore, these two groups of neurons were grown in the absence 
(PBS treatment) or the presence of ligand (IL-17 treatment), and fixed and imaged at D.I.V.13 
(Fig. 17A). The images taken at D.I.V.13 were analyzed for synapse puncta development by 

































Figure 17: Schematic of synapse puncta count assay protocol. (A) Primary cortical neurons 
were plated and grown for 4 days. At days in vitro (D.I.V.) 4, the genomes of the cells were 
edited by cleaving the sequences of IL17Ra or LacZ via the CRISPR/Cas9 technique. Guide 
RNA’s were fused with GFP. The cells were then grown for 9 more days at the absence of (PBS 
treatment) or the presence of ligand (IL-17 treatment). At D.I.V.13, all cells were fixed ad 
imaged. (B) The imaged cells were then analyzed for synapse puncta formation via the software 
ImageJ. All synapse puncta on the neurites, represented by synapsin I staining (red), 50µm away 
from the cell body were counted for 50µm (yellow line). Then, the synapse puncta count of 
various groups and treatment types were compared. All cells were stained for GFP (green) and 
synapsin I (red). All images were taken at 40X magnification. Scale bar indicates 30µm. 
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Treatment of ligand IL-17 suppresses synapse puncta formation in wild type primary 
cortical neurons upon IL17Ra loss-of-function 
 
 In wild type primary cortical neurons with LacZ KD, there was no difference in synapse 
puncta count between PBS and IL-17 treated neurons (Fig. 18A). Surprisingly, upon IL17Ra KD, 
treatment of IL-17 induced differences in synapse puncta count. Quantification showed that 
neurons treated with IL-17 had about 1.4 times less synapse puncta formation than those grown 












Figure 18: Treatment of ligand has no effect on LacZ KD wild type primary cortical 
neurons, but suppresses puncta formation in IL17Ra KD neurons. Synapse puncta formation 
in wild type primary cortical neurons with LacZ KD (purple) or IL17Ra KD (orange) was 
measured. (A) LacZ KD neurons showed the same level of synapse puncta formation when 
cultured in the absence (no pattern) or presence of IL-17 (patterned). (B) However, IL-17 
treatment suppressed synapse formation in IL17Ra KD neurons (patterned) compared to that of 
control neurons (no pattern). All bars represent mean + s.e.m. Unpaired t-test; **p<0.01. 
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IL17Ra loss-of-function in wild type primary cortical neurons suppresses puncta formation 
in the presence of ligand IL-17 
 
Upon quantification, the wildtype neurons that expressed endogenous levels of IL17Ra 
(LacZ KD) and those that underexpressed IL17Ra (IL17Ra KD) developed the same number of 
puncta at D.I.V. 13, when grown in the absence of ligand (Fig. 19A). In the presence of ligand, 



























Figure 19: IL17Ra loss-of-function in wildtype primary cortical neurons inhibits synapse 
puncta formation when treated with ligand. The role of IL17Ra in synapse puncta formation 
was studied using primary cortical neurons with endogenous IL17Ra (LacZ KD) and with 
IL17Ra loss-of-function (IL17Ra KD). (A) Neurons with LacZ KD (purple) or IL17Ra KD 
(orange) did not differ in synapse puncta count when grown in the absence of ligand. (B) The 
presence of ligand suppressed synapse puncta formation in IL17Ra KD neurons. All bars 
represent mean + s.e.m. ** p<0.01.  
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Overexpression of IL17Ra in non-neuronal cells inhibits synapse formation 
 
In addition to the synapse puncta assay, we attempted to characterize the role of IL17Ra 
in synapse formation using the artificial synapse assay. We observed synapse formation between 
primary cortical neurons and HEK293 cells for the following reasons: (i) Cell adhesion 
molecules that are transfected onto non-neuronal cells are known to form stable junctions with 
neuronal cells; (ii) Previous studies show that this interaction between neuronal and non-
neuronal cells induces similar differentiation processes that occur between neuronal cells upon 
synapse formation; (iii) Directly transfecting proteins onto neuronal cells is much more difficult 
to do because primary neuronal cultures are very sensitive to environmental changes; and (iv) 
Results from the artificial synapse formation assay will provide a functional readout of the 
synaptic adhesive properties of IL17Ra (49, 50). 
In this assay, non-neuronal HEK293 cells overexpressing IL17Ra (transfected with 
IL17Ra-CFP) or endogenous levels of IL17Ra (transfected with blank-BFP) were seeded onto 
primary cortical neurons of wild type (WT) or maternal immune activated (MIA) animals. The 
cells were co-cultured for 2 days, and fixed and stained via immunocytochemistry using 
antibodies that targeted the presynaptic protein synapsin I (Fig. 20A). Synapse formation was 
then quantified by measuring the intensity of synapsin I expression, in the areas that co-localized 



















Figure 20: Schematic of artificial synapse formation assay protocol. (A) Primary cortical 
neurons from maternal immune activated (MIA) and WT animals were plated and grown for 10 
days. At days in vitro (D.I.V.) 10, HEK293 cells transfected with IL17Ra or mock vectors were 
added. Cells were then fixed at D.I.V.12 and stained. (B) The imaged cells were analyzed for 
artificial synapse formation using the software program ImageJ. Synapse formation, represented 
by synapsin I intensity (red), was measured by analyzing the co-localization of transfected 
HEK293 cells and synapsin I staining. All images were taken at 40X magnification. Scale bar is 
indicative of 30µm.  
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Wild type primary cortical neurons co-cultured with non-neuronal cells overexpressing 
IL17Ra visibly showed inhibited synapse formation compared to those co-cultured with control 
cells alone (Fig. 20B). In MIA neurons, synapse formation was inhibited when co-cultured with 
non-neuronal transfected with blank vectors, and this inhibition was amplified when co-cultured 
with non-neuronal cells expressing IL17Ra (Fig. 20B).  
Quantification showed that MIA neurons co-cultured with IL17Ra-overexpressing non-
neuronal cells formed about 3 times fewer synapses than those co-cultured with control non-
neuronal cells (Fig. 21A). Furthermore, wild type neurons co-cultured with IL17Ra-
overexpressing non-neuronal cells exhibited slightly inhibited, but insignificant, synapse 















Figure 21: Synapse formation is inhibited when IL17Ra is overexpressed in non-neuronal 
cells. Non-neuronal cells transfected with IL17Ra or blank vectors were co-cultured with 
primary cortical neurons from MIA (purple) or wild type (orange) animals to determine the role 
of IL17Ra in synapse formation. (A) MIA neurons co-cultured with IL17Ra-overexpressing 
HEK293 cells resulted in 3 times less synapse formation than those co-cultured with blank 
HEK293 cells. (B) WT neurons co-cultured with IL17Ra-overexpressing showed slightly 
inhibited, but non-significant, synapse formation compared to those co-cultured with mock 
vector transfected cells. All bars represent mean + s.e.m. ****p<0.0001.    
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Synapse formation is further inhibited in MIA primary cortical neurons 
 
 In addition to comparing the effects in synapse formation when IL17Ra is overexpressed 
in non-neural cells, we observed the effects of animal type. The general trend of inhibition in 
synapse formation when IL17Ra is overexpressed in non-neural cells was similar between the 
two groups, wild type and MIA neurons. However, MIA animals was further impaired in their 


















Figure 22: Synapse formation in maternal immune activated (MIA) primary cortical 
neurons is impaired. Non-neuronal cells transfected with IL17Ra or blank vectors were co-
cultured with primary cortical neurons from MIA (purple) or wild type (orange) animals to 
determine the role of IL17Ra in synapse formation.  IL17Ra expression in non-neuronal cells 
impaired synapse formation in wild type neurons slightly, as shown by the % decrease in 
baseline synapse formation between wild type neurons and control cells. This pattern is also 
observed in MIA neurons as well; however the inhibitory effects are much more amplified. All 
bars represent mean + s.e.m.  
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Discussion 
 The purpose of the synapse puncta and artificial synapse formation assays were to 
characterize the role of IL17Ra as a cell adhesion molecule that facilitates synapse formation in 
primary cortical neurons. Contrary to our hypothesis that IL17Ra will aid synapse formation, 
thus decreasing synapse puncta formation upon loss-of-function and increasing artificial synapse 
formation with IL17Ra-overexpressing HEK293 cells, our results indicate that IL17Ra inhibits 
synapse formation.  
 In the synapse puncta assay, there was no difference in synapse puncta count between 
control and IL17Ra KD neurons when treated with PBS; however, when they were treated with 
IL-17, IL17Ra KD neurons developed less synapse puncta (Fig. 19). These results may be 
because the largest increase in neurite outgrowth was observed in IL-17 treated IL17Ra KD 
neurons, and therefore the synapse puncta may have been more spread out. Furthermore, we 
recognize the limitations of counting the number of synapse puncta for only 50µm of the neurites. 
Future studies will involve normalizing the each assay by measuring the synaptic density per 
neurite length in order to make more definitive conclusions regarding synapse puncta formation. 
 In the artificial synapse formation assay, synapse formation between MIA primary 
cortical neurons and blank HEK293 cells was greatly inhibited, and even further inhibited when 
the HEK293 cells overexpressed IL17Ra (Fig. 21A). Although a slight inhibition in synapse 
formation was observed between wild type primary cortical neurons and IL17Ra overexpressing 
HEK293 cells, the level of synapse formation did not differ significantly from that of wild type 
neurons and blank HEK293 cells (Fig. 21B). These results suggest IL17Ra has an inhibitory role 
in cell adhesion, and therefore suppresses synapse formation as well. Additionally, MIA neurons 
overexpress IL17Ra, further supporting this notion (33). 
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One may question whether or not synapsin I intensity is indicative of synapse formation. 
Although more accurately described as measuring contact between the neuronal and non-
neuronal cells, many previous studies have confirmed that the differentiation processes that 
occur upon contact is representative of synapse formation that occurs between neuronal cells (41, 
49, 50). Furthermore, our results from the artificial synapse formation assay are consistent with 
our findings from the cell aggregation and neurite outgrowth assays. Cell adhesion is a crucial 
element in synapse formation (42), and if IL17Ra has an inhibitory role, it is logical that synapse 
formation would also be inhibited in IL17Ra-overexpressing cells. However, future studies are 
needed to further elucidate the role and mechanism of IL17Ra in synapse formation. Although 
more difficult to do, analyzing synapse formation between cortical neurons via transfecting 
IL17ra onto neurons would yield more meaningful and translatable results. Lastly, confirming 
our results from the synapse puncta and artificial synapse assays using primary cortical neurons 
of IL17Ra knockout mice to measure the effects of complete IL17Ra loss-of-function would 
strengthen our hypothesis. 
Putting our results into larger context, proper regulation of cell adhesion molecules is 
extremely critical, as cell adhesion molecules have central roles during the processes of cell 
adhesion, axon fasciculation, cell motility and neurite outgrowth, and synaptogenesis in 
neurodevelopment (42). However, the downregulation of these molecules is equally important, 
especially because these processes require some degree of inhibition in order for the neurons to 
detach, change directions, and prune synapses (40). Based on our results, here we propose a 
mechanism that involves IL17Ra in synapse formation. Wild type neurons form a stable level of 
connection via other endogenous cell adhesion molecules (Fig. 23A). This stable level of 
synapse formation is slightly disrupted when the non-neuronal cells overexpress IL17Ra, as 
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IL17Ra plays an inhibitory role (Fig. 23B). However, in MIA neurons that overexpress IL17Ra, 
this inhibitory effect is amplified (Fig. 23C), and even further amplified when the non-neuronal 
cells overexpress IL17Ra as well (Fig. 23D). Again, it is important to recognize the limitations, 
as well as the advantages, of in vitro assays. With further well-designed and well-controlled 







Figure 23: A proposed model for the role of IL17Ra during synapse formation. (A) Stable 
synapse formation between wild type primary cortical neurons and non-neuronal cells requires 
the aid of endogenous cell adhesion molecules. (B) This stable cell-to-cell synapse formation is 
disrupted when IL17Ra is overexpressed in the non-neuronal cell. (C) In MIA neurons that 
presynaptically overexpress IL17Ra, synapse formation is even more inhibited. (D) This 
inhibition effect is further amplified when the non-neuronal cell overexpresses IL17Ra as well. 
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CHAPTER 5: GENERAL DISCUSSION 
 
Potential role of IL17Ra in the pathogenesis of ASD 
 
 The IL-17 cytokine family plays an important role in the regulation of immune response. 
A recent study identified the cellular source of the cytokine IL-17 that is necessary and sufficient 
to induce ASD-like phenotypes in MIA offspring, and showed that the mRNA levels of the 
cognate receptor of IL-17, IL17Ra, in the offspring are elevated upon MIA (33). Further 
elucidation of the IL17Ra signaling pathway would allow better understanding of how the 
downstream mediators induce abnormal cortical and behavioral phenotypes. Here, our results 
reveal an interesting link between immune response and the role of IL17Ra in the brain, as 
IL17Ra may have differing roles in various neurodevelopmental processes of cell adhesion, 
neurite outgrowth, and synapse formation.  
 It is worthwhile to note that some studies have suggested that IL17Ra may have normal 
developmental functions, and it is the overexpression and thus the hyperactivity of IL17Ra that 
disrupts normal neurodevelopment (33, 45). On the same note, here we propose a mechanism by 
which IL17Ra is involved in normal neurodevelopment, and upon overexpression, can lead to 
disruption in various neurodevelopmental processes. More specifically, we hypothesize that 
IL17Ra acts as an inhibitory protein that disrupts cell adhesion, and therefore possibly disrupts 
critical processes that require adhesion such as neurite outgrowth and synapse formation. For 
example, IL17Ra may activate downstream pathways that disrupt cell adhesion of other 
endogenous cell adhesion molecules that facilitate adhesion between cells (Fig. 24A). IL17Ra 
may also activate proteases that downregulate the expression of other cell adhesion molecules 
(Fig. 24B). Finally, our data most strongly suggest that IL17Ra has other binding partners that 
upon interaction destabilize cell adhesion (Fig. 24C). A growing body of evidence supports the 
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notion that IL17Ra signaling is critically involved in inducing ASD, and further studies are 
required to elucidate the exact mechanisms of this pathway. 
 Consistent with our results, many other studies also support the notion that cytokine-
induced disruptions of neurodevelopmental sequences underlie the pathogenesis of ASD. For 
example, studies attribute one of the contributing factors of ASD to the dysregulation of the cell 
cycle, as shown by increased proliferation of radial glial cells (51) or decreased number of 
precursor cells, due to cytokine dysregulation and abnormal microglial activity (52). 
Additionally, others attribute the disruption of cell migration, and therefore disorganized laminar 
positioning, to the cause of ASD (53). On a similar note, abnormal cortical phenotypes observed 
in MIA-induced ASD-like offspring showed corresponding patterns of disorganized cortical 
Figure 24: The potential role of IL17Ra in during cortical development. (A) IL17Ra 
activates downstream pathways to disrupt the interaction between other endogenous cell 
adhesion molecules. (B) IL17Ra activates proteases that down-regulate the expression of other 
endogenous cell adhesion molecules. (C) IL17Ra has other binding partners that upon binding, 
destabilizes adhesion. However, when its ligand IL-17, for which it has higher affinity for, binds, 
IL17Ra no longer binds to its binding partner and cell adhesion is not disrupted.  
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patches seen in postmortem analyses of human ASD brains (33, 44). Finally, studies also show 
that the disruption of cell adhesion between synapses, and therefore the failure to initialize, 
specify, maintain, or regulate synapse formation, may underlie the pathogenesis of ASD. 
Consistent with this notion, recent studies indicate that various synaptic cell adhesion molecules 
may be candidate genes for various cognitive consequences in ASD (41, 54-56). Most 
importantly, another receptor of the cytokine family, IL1RcP, is a well-
characterized cell adhesion molecule that organizes neuronal synaptogenesis 
(41). This suggests the possibility that cytokine signals converge on similar proteins to regulate 
processes of development, such as synaptogenesis.  
 
Therapeutic and preventative implications 
Currently, therapeutic intervention primarily focuses on behavioral therapies to control 
the behaviors of individuals affected with ASD. Moreover, some preventative measures that 
already exist include getting vaccinated, improving personal hygiene, and using contraceptives to 
prevent illnesses during gestation (57). Preventative and therapeutic intervention, as well as 
accurate diagnostic measures of ASD are all critically lacking. 
Recent research, however, has strongly established the role of MIA as an underlying risk 
factor of ASD. Although more studies are required, these results that link maternal immune 
response and ASD has significant public health implications. Many studies have revealed the 
detrimental effects of the elevated cytokine levels, as well as have succeeded in manipulating 
cytokine levels to prevent ASD-like behaviors after MIA induction (18, 33, 58). For example, 
blocking IL-17 activity in the mothers via knockout models or treating mothers with antibodies 
resulted in successful prevention of ASD-like phenotypes in the MIA model (33). Identification 
of Th17 cells and IL-17 as key regulators not only highlights a potential therapeutic target for 
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pharmacological intervention, but also at the potential biological marker for diagnosing ASD and 
early intervention. However, more research is needed since cytokines are extremely versatile, 
and thus may lead to unexpected consequences elsewhere (11). Further elucidation of the Th17/ 
IL-17 signaling pathway may eventually yield successful diagnostic measures and preventative 
interventions, as targeting of Th17 cells in conjunction with regulating IL17Ra expression in 
susceptible pregnant mothers may allow us to reduce the likelihood of bearing children with 

























MATERIALS AND METHODS 
 
Animals 
All experiments were performed according to the Guide for the Care and Use of Laboratory 
Animals and were approved by the Committee and Animal Care at the Massachusetts Institute of 
Technology. C57BL/6 mice were obtained from Taconic (USA).   
 
Maternal Immune Activation 
Mice were mated overnight and females were checked daily for the presence of seminal plugs, 
noted as embryonic day 0.5 (E0.5). On E12.5, pregnant female mice were weighed and injected 
with a single dose (20mg/kg; i.p.) of poly(I:C) (Sigma Aldrich) or saline vehicle.  
 
Cell Preparation 
Human embryonic kidney (HEK) cell line 293FT (Life Technologies) was cultured in Dulbecco’s 
modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (Hyclone), 50mM 
HEPES, 50U penicillin-streptomycin (Invitrogen), and 2 mM glutamine. 293FT cells were 
seeded into 6-well plates (Corning) 24 h prior to transfection at a density of 1x106 cells/well. In 
preparation of cell aggregation assay and primary cultured neuron artificial synapse assay, cells 
were transfected with 1500ng plasmids/well using Lipofectamine 2000 (Life Technologies) 
following the manufacturer’s recommended protocol. 
Coverslips were incubated in 100% EtOH for 30 min at 37°C. Sterilized coverslips were then 
coated overnight with PDL (Sigma) at 37°C. Wild-type or MIA E12.5 embryos at each 
implantation site were dissected in ice-cold dissection media (DM) (HBSS (Invitrogen) 
containing 1% (v/v) HEPES, and 50U penicillin-streptomycin (Invitrogen)). Dissected cerebral 
cortical tissue were then minced and enzymatically dissociated in DM containing 2% Trypsin 
(Invitrogen) for 12 min at 37°C with intermittent mixing. Digested tissues were washed with DM 
and centrifuged 1000rpm for 1 min at 4°C three times. After washing coated coverslips with 
PBS, cells (5x104 cells/mL) were seeded into each of the 24-well plates (Corning) and cultured 
for 4 days in neurobasal media (Invitrogen) supplemented with 2mM glutamine (Sigma) and 
1mM B-27 (In.vitrogen). In preparation of primary cultured morphology and synapse assays, IL-
6 (Ebioscience) and IL-17a (Biolgened) were measured according to the manufacturer’s 
protocol.  
 
Cell Aggregation Assay 
Transfected 293FT cells were trypsinized and centrifuged at 2000rpm for 1 min. The pellet was 
resuspended in aggregation harvest buffer (DMEM supplemented with 50mM HEPES and 10% 
FBS with or without 10mM CaCl2). Different transfected 293FT cells were combined into 
1500µL microcentrifuge tubes, treated with PBS, IL-17a, or IL-6, and placed on shaker for 24 h. 
Samples were taken at 0, 2, 4, 24 h upon resuspension and imaged using a confocal microscope 
(LSM710; Carl Zeiss) with a 10X objective lens; all image settings were kept constant. 
 
Images were then analyzed using the software program ImageJ. In the control group, the areas 
of all single cells and cell aggregates at each imaging time point were measured (Fig. 9A). The 
averaged area of the single cells at 0 h was defined as baseline. Baseline values were eliminated 
from 2, 4, and 24 h data to normalize across the repeated trials, and then percent difference of 
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cell area from baseline was calculated to determine the normalized degree of cell aggregation. 
This analysis procedure was repeated for the IL17Ra overexpressing experimental group.  
 
Primary Cultured Neuron Morphology Assay 
4 days in vitro (d.i.v) after WT primary neuronal cell preparation, IL-17Ra (12 wells) or LacZ 
(12 wells) was knocked down using CRISPR/Cas9 genome editing as described elsewhere (59). 
Each IL-17Ra or LacZ knockdown group was treated with IL-17a (4 wells; 50µg/mL), IL-6 (4 
wells; 50µg/mL), or PBS (4 wells) at d.i.v. 5. Fresh neurobasal media was added every 4 days. 
Each of the treatment groups was fixed at d.i.v. 6, 9, 12, and 15 with 4% paraformaldehyde in 
PBS for 10 min at 4oC in preparation for immunocytochemistry.  
 
Cells were permeabilized with blocking solution containing 0.4% Triton X-100, 2% goat serum, 
and 1% BSA in PBS for 1 h at room temperature, and then incubated with anti-beta actin 
(ab8229, Abcam), anti-synapsin I (ab8, Abcam) and anti-GFP (ab13970, Abcam) antibodies 
diluted 1:1000 overnight at 4 oC. The following day, cells were incubated with fluorescently 
conjugated secondary antibodies (Invitrogen, USA) diluted 1:250 for 1 h at room temperature, 
and mounted in vectashield mounting medium with DAPI (Vector laboratories). Images of 
stained cells were acquired using a confocal microscope (LSM710; Carl Zeiss) with a 20X 
objective lens; all image settings were kept constant. 
 
Images were then analyzed using ImageJ. For the neurite outgrowth assay, the lengths (µm) of 
neurites, defined as processes between two somas, were measured and averaged for each 
experimental group (Fig. 13B). For the synapse puncta count assay, the number of puncta 
(represented by synapsin I expression) within 50µm of the neurite was measured and averaged 
for each experimental group (Fig. 17B).  
 
Primary Cultured Neuron Artificial Synapse Assay 
At d.i.v. 4 after WT or MIA neuronal cell preparation, fresh neurobasal media was added. At 
d.i.v. 9, 293FT cells were transfected with Lipofectamine 2000 and 1500ng of plasmids/well 
following the manufacturer’s recommended protocol. At d.i.v. 10, transfected 293FT cells were 
trypsinized and centrifuged at 2000rpm. The 293FT cells were resuspended in fresh neurobasal 
media and 2x103 293FT cells were added to each neuronal well plate. Fresh neurobasal media 
were added every 4 days. At d.i.v. 13, cells were fixed with 4% paraformaldehyde in PBS for 10 
min at 4oC in preparation for immunocytochemistry.  
 
Fixed samples were then permeabilized with blocking solution containing 0.4% Triton X-100, 2% 
goat serum, and 1% BSA in PBS for 1 h at room temperature, and then incubated with anti-
synapsin I (ab8, Abcam) diluted 1:1000 overnight at 4 oC. The following day, cells were 
incubated with fluorescently conjugated secondary antibodies (Invitrogen, USA) diluted 1:250 
for 1 h at room temperature, and mounted in vectashield mounting medium (Vector laboratories). 
Images of stained cells were acquired using a confocal microscope (LSM710; Carl Zeiss) with a 
40X objective lens; all image settings were kept constant. 
 
Images were then analyzed using ImageJ. Co-localization of BFP (control) or CFP (IL17Ra) 
and synapsin I was used as a measure of synapse formation (Fig. 20B). Measurements of 
synapse formation was averaged and compared across different experimental groups.  
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Statistical analysis 
Results from cell aggregation assay and primary neuron culture assays were analyzed using 
unpaired, paired t-tests, and one-way ANOVAs. When statistical comparisons were made 









































Confirmation of IL17Ra expression levels in HEK293 cells 
The endogenous IL17Ra levels in HEK293 cells were determined via real-time PCR (RT-
PCR). Wild type primary cortical neurons and HEK293 cells endogenously express the same 
level of IL17Ra (Fig. S1). In HEK293 cells, IL17Ra expression is primarily localized to the 










Supplemental Figure 1: HEK293 cells and primary cortical neurons endogenously express 
similar levels of IL17Ra. (A) Primary cortical neurons (pink) and HEK293 cells (purple) 
express same endogenous levels of IL17Ra. Real-time PCR was done to determine levels of 
IL17Ra expression. All bars indicate mean + s.e.m. (B) IL17Ra expression is localized to the cell 










Confirmation of IL17Ra KD in primary cortical neurons 
  20-nucleotide guide RNA (gRNA) was designed to target il17ra using the CRISPR/Cas9 
single guide strategy targeting technique (Fig. S2A). Because a reliable IL17Ra antibody is yet to 
be made, CRISPR/Cas9 genome editing of IL17Ra was confirmed via a SURVEYOR nuclease 
assay. The SURVEYOR gel shows successful modification at the gRNA loci in wild type 










Supplemental Figure 2: CRISPR/Cas9 single guide strategy targeting il17Ra. A. The 
expected target sequence of Cas9 and its guide RNA (gRNA). B. SURVEYOR nuclease assay 
confirmation of IL17Ra genome editing in wild type primary cortical neurons, as indicated by 




Figure 11: Cell Aggregation Assay – PBS Treatment 
Time point Statistical Analysis 
2 HR Unpaired t-test; p<0.01, t=3.148, df=362 
4 HR Unpaired t-test; p<0.001, t=3.681, df=388 
24 HR Unpaired t-test; p<0.0001, t=4.305, df=171 
 
Figure 12: Cell Aggregation Assay – IL-17 Treatment 
Time point Statistical Analysis 
2 HR Unpaired t-test; p<0.05, t=2.022, df=256 
4 HR Unpaired t-test; p<0.0001, t=4.632, df=400 
24 HR Unpaired t-test; p-0.121, t=1.561, df=124 
 
Figure 13: Cell Aggregation Assay – Combined 
One-way ANOVA; p<0.001, F(3, 295)=6.795 
 
Figure 16: Neurite Outgrowth Assay – PBS vs. IL-17 Treatment 
Group Statistical Analysis 
LacZ KD Paired t-test; p<0.0001, t=6.529, df=34 
IL17Ra KD Paired t-test; p<0.0001, t=5.694, df=63 
 
 
Figure 17: Neurite Outgrowth Assay – LacZ KD vs. IL17Ra KD 
Treatment Type Statistical Analysis 
PBS Paired t-test; p<0.01, t=3.418, df=34 
IL-17 Paired t-test; p<0.0001, t=7.317, df=116 
 
Figure 20: Synapse Puncta Assay – PBS vs. IL-17 Treatment 
Genetic Group Statistical Analysis 
LacZ KD Paired t-test; p=0.7311, t=0.3479, df=23 
IL17Ra KD Paired t-test; p<0.0001, t=5.222, df=43 
 
Figure 21: Synapse Puncta Assay – LacZ KD vs. IL17Ra KD 
Treatment Type Statistical Analysis 
PBS Paired t-test; p=0.0857, t=1.796, df=23 
IL-17 Paired t-test; p<0.01, t=3.06, df=43 
 
Figure 23: Synapse Puncta Assay – IL17Ra overexpressing vs. Mock (Control) 
Animal Type Statistical Analysis 
MIA Unpaired t-test; p<0.0001, t=5.471, df=66 
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